(Q36617998)

English

Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer's disease receiving donepezil

scientific article published on 15 February 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer's disease receiving donepezil (English)

1 reference

Europe PubMed Central

15 August 2017

Alzheimer's disease

0 references

author name string

Osamu Kano

1

1 reference

Europe PubMed Central

15 August 2017

Hirono Ito

2

1 reference

Europe PubMed Central

15 August 2017

Takanori Takazawa

3

1 reference

Europe PubMed Central

15 August 2017

Yuji Kawase

4

1 reference

Europe PubMed Central

15 August 2017

Kiyoko Murata

5

1 reference

Europe PubMed Central

15 August 2017

Konosuke Iwamoto

6

1 reference

Europe PubMed Central

15 August 2017

Tetsuro Nagaoka

7

1 reference

Europe PubMed Central

15 August 2017

Takehisa Hirayama

8

1 reference

Europe PubMed Central

15 August 2017

Ken Miura

9

1 reference

Europe PubMed Central

15 August 2017

Riya Nagata

10

1 reference

Europe PubMed Central

15 August 2017

Tetsuhito Kiyozuka

11

1 reference

Europe PubMed Central

15 August 2017

Jo Aoyagi

12

1 reference

Europe PubMed Central

15 August 2017

Ryuta Sato

13

1 reference

Europe PubMed Central

15 August 2017

Teruo Eguchi

14

1 reference

Europe PubMed Central

15 August 2017

Ken Ikeda

15

1 reference

Europe PubMed Central

15 August 2017

Yasuo Iwasaki

16

1 reference

Europe PubMed Central

15 August 2017

language of work or name

0 references

publication date

15 February 2013

1 reference

Europe PubMed Central

15 August 2017

Neuropsychiatric Disease and Treatment

1 reference

Europe PubMed Central

15 August 2017

9

1 reference

Europe PubMed Central

15 August 2017

259-265

1 reference

Europe PubMed Central

15 August 2017

copyright license

Creative Commons Attribution-NonCommercial 3.0 Unported

1 February 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

30 September 2017

Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

30 September 2017

Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

30 September 2017

Cholinesterase inhibitors: A new class of psychotropic compounds

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

30 September 2017

The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

30 September 2017

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

30 September 2017

Glutamate: A Neurotransmitter in Mammalian Brain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

30 September 2017

“Mini-mental state”

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

30 September 2017

Clinical global impressions in Alzheimer's clinical trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

30 September 2017

Maintaining functional and behavioral abilities in Alzheimer disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

28 June 2018

The Neuropsychiatric Inventory: assessing psychopathology in dementia patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

28 June 2018

[Japanese version of the Neuropsychiatric Inventory--a scoring system for neuropsychiatric disturbance in dementia patients]

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

28 June 2018

Two galantamine titration regimens in patients switched from donepezil.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

20 September 2018

Donepezil for the treatment of agitation in Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

20 September 2018

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

20 September 2018

Switching from donepezil or rivastigmine to galantamine in clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

20 September 2018

Assessment of agitation in elderly patients with dementia: correlations between informant rating and direct observation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

20 September 2018

[Cohen-Mansfield Agitation Inventory (CMAI)].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

20 September 2018

Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

20 September 2018

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

20 September 2018

Agitation in Alzheimer’s Disease Is a Manifestation of Frontal Lobe Dysfunction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

20 September 2018

Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

20 September 2018

The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

20 September 2018

Memantine in moderate-to-severe Alzheimer's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

20 September 2018

The incremental direct costs associated with behavioral symptoms in AD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

20 September 2018

Noradrenergic changes, aggressive behavior, and cognition in patients with dementia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

20 September 2018

Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

20 September 2018

NMDA receptor-dependent synaptic reinforcement as a crucial process for memory consolidation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

20 September 2018

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

20 September 2018

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3575212

20 September 2018

Identifiers

10.2147/NDT.S40682

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36617998&oldid=1865613130"